You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLornoxicam
Accession NumberDB06725
TypeSmall Molecule
GroupsApproved
DescriptionLornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. Lornoxicam is approved for use in Japan.
Structure
Thumb
Synonyms
Chlortenoxicam
Lornoxicamum
External Identifiers
  • CCRIS 8589
  • Ro 13-9297
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LorcamTaisho Pharmaceutical Co.
XafonNycomed
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIER09126G7A
CAS number70374-39-9
WeightAverage: 371.81
Monoisotopic: 370.9801259
Chemical FormulaC13H10ClN3O4S2
InChI KeyWLHQHAUOOXYABV-UHFFFAOYSA-N
InChI
InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)
IUPAC Name
6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1λ⁶-thieno[2,3-e][1,2]thiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acids and derivatives
Alternative Parents
Substituents
  • Alpha-amino acid or derivatives
  • Thienothiazine
  • N-arylamide
  • 2,3,5-trisubstituted thiophene
  • Ortho-thiazine
  • Aryl chloride
  • Aryl halide
  • Pyridine
  • Organosulfonic acid amide
  • Imidolactam
  • Heteroaromatic compound
  • Organic sulfonic acid or derivatives
  • Organosulfonic acid or derivatives
  • Thiophene
  • Vinylogous acid
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Organic oxide
  • Hydrocarbon derivative
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases.
PharmacodynamicsLornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the oxicam class. As with other NSAIDS, lornoxicam is a potent inhibitor of the cyclooxgenase enzymes, which are responsible for catalyzing the formation of prostaglandins (act as messenger molecules in the process of inflammation) and thromboxane from arachidonic acid. Unlike some NSAIDS, lornoxicam's inhibition of cyclooxygenase does not lead to an increase in leukotriene formation, meaning that arachidonic acid is not moved to the 5-lipoxygenase cascade, resulting in the minimization of the risk of adverse events.
Mechanism of actionLike other NSAIDS, lornoxicam's anti-inflammatory and analgesic activity is related to its inhibitory action on prostaglandin and thromboxane synthesis through the inhibition of both COX-1 and COX-2. This leads to the reduction of inflammation, pain, fever, and swelling, which are mediated by prostaglandins. However, the exact mechanism of lornoxicam, like that of the other NSAIDs, has not been fully determined.
Related Articles
AbsorptionLornoxicam is absorbed rapidly and almost completely from the GI tract (90-100%).
Volume of distributionNot Available
Protein bindingLornoxicam is 99% bound to plasma proteins (almost exlusively to serum albumin).
Metabolism

Lornoxicam is metabolized completely by cyp 2C9 with the principal metabolite being 5'-hydroxy-lornoxicam and only negligible amounts of intact lornoxicam are excreted unchanged in the urine. Approximately 2/3 of the drug is eliminated via the liver and 1/3 via the kidneys in the active form.

SubstrateEnzymesProduct
Lornoxicam
5'-HydroxylornoxicamDetails
Route of eliminationNot Available
Half life3-5 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Lornoxicam Action PathwayDrug actionSMP00700
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier-0.964
Caco-2 permeable+0.7528
P-glycoprotein substrateSubstrate0.5511
P-glycoprotein inhibitor INon-inhibitor0.8209
P-glycoprotein inhibitor IINon-inhibitor0.8506
Renal organic cation transporterNon-inhibitor0.9132
CYP450 2C9 substrateSubstrate0.6831
CYP450 2D6 substrateNon-substrate0.8868
CYP450 3A4 substrateNon-substrate0.6652
CYP450 1A2 substrateNon-inhibitor0.7958
CYP450 2C9 inhibitorInhibitor0.7138
CYP450 2D6 inhibitorNon-inhibitor0.8714
CYP450 2C19 inhibitorNon-inhibitor0.7777
CYP450 3A4 inhibitorNon-inhibitor0.8755
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7815
Ames testNon AMES toxic0.8009
CarcinogenicityNon-carcinogens0.6844
BiodegradationNot ready biodegradable0.9851
Rat acute toxicity3.8570 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9494
hERG inhibition (predictor II)Non-inhibitor0.8681
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.62BIOBYTE STARLIST (2009)
Predicted Properties
PropertyValueSource
Water Solubility0.0437 mg/mLALOGPS
logP3.08ALOGPS
logP0.64ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)1.82ChemAxon
pKa (Strongest Basic)4.22ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity87.9 m3·mol-1ChemAxon
Polarizability33.3 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Balfour JA, Fitton A, Barradell LB: Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57. [PubMed:8706598 ]
  2. Vane JR: Introduction: mechanism of action of NSAIDs. Br J Rheumatol. 1996 Apr;35 Suppl 1:1-3. [PubMed:8630629 ]
  3. Radhofer-Welte S, Rabasseda X: Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000 Jan;36(1):55-76. [PubMed:12879104 ]
  4. Skjodt NM, Davies NM: Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet. 1998 Jun;34(6):421-8. [PubMed:9646006 ]
  5. Olkkola KT, Brunetto AV, Mattila MJ: Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994 Feb;26(2):107-20. [PubMed:8162655 ]
  6. Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D: Pharmacokinetics of lornoxicam in man. Postgrad Med J. 1990;66 Suppl 4:S22-7. [PubMed:2284217 ]
  7. Pruss TP, Stroissnig H, Radhofer-Welte S, Wendtlandt W, Mehdi N, Takacs F, Fellier H: Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J. 1990;66 Suppl 4:S18-21. [PubMed:2284216 ]
  8. Bonnabry P, Leemann T, Dayer P: Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol. 1996;49(4):305-8. [PubMed:8857077 ]
External Links
ATC CodesM01AC05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabLornoxicam may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Lornoxicam can be decreased when combined with Abiraterone.
AcebutololLornoxicam may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Aceclofenac.
AcenocoumarolLornoxicam may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Lornoxicam.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Lornoxicam.
Alendronic acidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.
AliskirenLornoxicam may decrease the antihypertensive activities of Aliskiren.
AlprenololLornoxicam may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Lornoxicam.
AmikacinLornoxicam may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideLornoxicam may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Lornoxicam can be decreased when combined with Amiodarone.
AncrodLornoxicam may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Lornoxicam.
Antithrombin III humanLornoxicam may increase the anticoagulant activities of Antithrombin III human.
ApixabanLornoxicam may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Lornoxicam.
AprepitantThe metabolism of Lornoxicam can be increased when combined with Aprepitant.
ArdeparinLornoxicam may increase the anticoagulant activities of Ardeparin.
ArgatrobanLornoxicam may increase the anticoagulant activities of Argatroban.
ArotinololLornoxicam may decrease the antihypertensive activities of Arotinolol.
AtenololLornoxicam may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lornoxicam.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lornoxicam.
BalsalazideLornoxicam may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Lornoxicam.
BecaplerminLornoxicam may increase the anticoagulant activities of Becaplermin.
BefunololLornoxicam may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Lornoxicam.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lornoxicam.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lornoxicam.
BetaxololLornoxicam may decrease the antihypertensive activities of Betaxolol.
BevantololLornoxicam may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Lornoxicam.
BisoprololLornoxicam may decrease the antihypertensive activities of Bisoprolol.
BivalirudinLornoxicam may increase the anticoagulant activities of Bivalirudin.
BopindololLornoxicam may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lornoxicam.
BufuralolLornoxicam may decrease the antihypertensive activities of Bufuralol.
BumetanideLornoxicam may decrease the diuretic activities of Bumetanide.
BupranololLornoxicam may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Lornoxicam.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Lornoxicam.
CapecitabineThe metabolism of Lornoxicam can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Lornoxicam.
CarbamazepineThe metabolism of Lornoxicam can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lornoxicam.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Lornoxicam.
CarteololLornoxicam may decrease the antihypertensive activities of Carteolol.
CarvedilolLornoxicam may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lornoxicam.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Lornoxicam.
CeliprololLornoxicam may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Lornoxicam can be increased when it is combined with Ceritinib.
CertoparinLornoxicam may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lornoxicam.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lornoxicam.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lornoxicam.
CholecalciferolThe metabolism of Lornoxicam can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lornoxicam.
Citric AcidLornoxicam may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Lornoxicam.
ClotrimazoleThe metabolism of Lornoxicam can be decreased when combined with Clotrimazole.
ColesevelamColesevelam can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineLornoxicam may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Lornoxicam can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with D-Limonene.
Dabigatran etexilateLornoxicam may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Lornoxicam can be decreased when it is combined with Dabrafenib.
DalteparinLornoxicam may increase the anticoagulant activities of Dalteparin.
DanaparoidLornoxicam may increase the anticoagulant activities of Danaparoid.
DaunorubicinLornoxicam may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Deferasirox.
DelavirdineThe metabolism of Lornoxicam can be decreased when combined with Delavirdine.
DesirudinLornoxicam may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Lornoxicam.
DextranLornoxicam may increase the anticoagulant activities of Dextran.
Dextran 40Lornoxicam may increase the anticoagulant activities of Dextran 40.
Dextran 70Lornoxicam may increase the anticoagulant activities of Dextran 70.
Dextran 75Lornoxicam may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Lornoxicam.
DicoumarolLornoxicam may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lornoxicam.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lornoxicam.
DihydrostreptomycinLornoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Lornoxicam.
DoxorubicinLornoxicam may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneLornoxicam may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Droxicam.
Edetic AcidLornoxicam may increase the anticoagulant activities of Edetic Acid.
EdoxabanLornoxicam may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Lornoxicam can be decreased when combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Lornoxicam.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Lornoxicam.
EnoxaparinLornoxicam may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Epirizole.
EpirubicinLornoxicam may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneLornoxicam may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lornoxicam.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lornoxicam.
EsmololLornoxicam may decrease the antihypertensive activities of Esmolol.
Etacrynic acidLornoxicam may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Lornoxicam.
Ethyl biscoumacetateLornoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Lornoxicam.
EtofenamateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Lornoxicam.
EtravirineThe metabolism of Lornoxicam can be decreased when combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Lornoxicam.
FenbufenThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Lornoxicam.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Lornoxicam.
FloxuridineThe metabolism of Lornoxicam can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Lornoxicam can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flunixin.
FluorouracilThe metabolism of Lornoxicam can be decreased when combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lornoxicam.
FluvastatinThe metabolism of Lornoxicam can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Lornoxicam can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Lornoxicam.
Fondaparinux sodiumLornoxicam may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Lornoxicam.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lornoxicam.
FosphenytoinThe metabolism of Lornoxicam can be increased when combined with Fosphenytoin.
FramycetinLornoxicam may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideLornoxicam may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Lornoxicam.
GemfibrozilThe metabolism of Lornoxicam can be decreased when combined with Gemfibrozil.
GentamicinLornoxicam may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Haloperidol.
HeparinLornoxicam may increase the anticoagulant activities of Heparin.
HirulogLornoxicam may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Lornoxicam.
HydralazineLornoxicam may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lornoxicam.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lornoxicam.
Hygromycin BLornoxicam may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lornoxicam.
IbuproxamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Lornoxicam.
IdarubicinLornoxicam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lornoxicam.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lornoxicam.
IndenololLornoxicam may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Lornoxicam can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lornoxicam.
IndoprofenThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lornoxicam.
IsoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Isoxicam.
KanamycinLornoxicam may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Kebuzone.
KetoconazoleThe metabolism of Lornoxicam can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Lornoxicam.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Lornoxicam.
LabetalolLornoxicam may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Lornoxicam.
LepirudinLornoxicam may increase the anticoagulant activities of Lepirudin.
LevobunololLornoxicam may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Lornoxicam.
LithiumThe serum concentration of Lithium can be increased when it is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Lornoxicam.
LovastatinThe metabolism of Lornoxicam can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Lornoxicam.
LumacaftorThe serum concentration of Lornoxicam can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Lornoxicam.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lornoxicam.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lornoxicam.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lornoxicam.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lornoxicam.
MesalazineLornoxicam may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Lornoxicam.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Lornoxicam.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lornoxicam.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lornoxicam.
MetipranololLornoxicam may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lornoxicam.
MetoprololLornoxicam may decrease the antihypertensive activities of Metoprolol.
MetrizamideLornoxicam may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe serum concentration of Lornoxicam can be increased when it is combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Lornoxicam.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Lornoxicam.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Lornoxicam.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lornoxicam.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lornoxicam.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Lornoxicam.
NadololLornoxicam may decrease the antihypertensive activities of Nadolol.
NadroparinLornoxicam may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lornoxicam.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Lornoxicam.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Lornoxicam.
NeomycinLornoxicam may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Nepafenac.
NetilmicinLornoxicam may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe metabolism of Lornoxicam can be decreased when combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lornoxicam.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lornoxicam.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lornoxicam.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lornoxicam.
OlsalazineLornoxicam may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Lornoxicam.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Lornoxicam.
OmeprazoleThe metabolism of Lornoxicam can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Orgotein.
OtamixabanLornoxicam may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lornoxicam.
OxprenololLornoxicam may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lornoxicam.
PamidronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Parecoxib.
ParomomycinLornoxicam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololLornoxicam may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateLornoxicam may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Lornoxicam.
PhenindioneLornoxicam may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Lornoxicam can be increased when combined with Phenobarbital.
PhenprocoumonLornoxicam may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lornoxicam.
PhenytoinThe metabolism of Lornoxicam can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lornoxicam.
PindololLornoxicam may decrease the antihypertensive activities of Pindolol.
PiretanideLornoxicam may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lornoxicam.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lornoxicam.
PlicamycinLornoxicam may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Lornoxicam.
PractololLornoxicam may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Lornoxicam.
PrimidoneThe metabolism of Lornoxicam can be increased when combined with Primidone.
ProbenecidThe serum concentration of Lornoxicam can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Propacetamol.
PropranololLornoxicam may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Lornoxicam.
Protein CLornoxicam may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeLornoxicam may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Lornoxicam.
PuromycinLornoxicam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Lornoxicam can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Lornoxicam.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lornoxicam.
QuinineThe metabolism of Lornoxicam can be decreased when combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Lornoxicam.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lornoxicam.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lornoxicam.
ReviparinLornoxicam may increase the anticoagulant activities of Reviparin.
RibostamycinLornoxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe metabolism of Lornoxicam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Lornoxicam can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Risedronate.
RivaroxabanLornoxicam may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Lornoxicam.
SalicylamideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lornoxicam.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Lornoxicam.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lornoxicam.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Lornoxicam.
SecobarbitalThe metabolism of Lornoxicam can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Seratrodast.
SildenafilThe metabolism of Lornoxicam can be decreased when combined with Sildenafil.
SorafenibThe metabolism of Lornoxicam can be decreased when combined with Sorafenib.
SotalolLornoxicam may decrease the antihypertensive activities of Sotalol.
SpectinomycinLornoxicam may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Lornoxicam.
SpironolactoneLornoxicam may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Lornoxicam.
StreptomycinLornoxicam may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinLornoxicam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Lornoxicam can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Lornoxicam can be decreased when combined with Sulfamethoxazole.
SulfasalazineLornoxicam may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lornoxicam.
SulfisoxazoleThe metabolism of Lornoxicam can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Lornoxicam.
SulodexideLornoxicam may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Lornoxicam.
TacrolimusLornoxicam may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Lornoxicam.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lornoxicam.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lornoxicam.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Lornoxicam.
TenofovirThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Lornoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lornoxicam.
TicagrelorThe metabolism of Lornoxicam can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Lornoxicam can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tiludronate.
TimololLornoxicam may decrease the antihypertensive activities of Timolol.
TobramycinLornoxicam may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolbutamideThe metabolism of Lornoxicam can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lornoxicam.
TorasemideLornoxicam may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Lornoxicam.
TranilastThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lornoxicam.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lornoxicam.
TriamtereneLornoxicam may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lornoxicam.
TrimethoprimThe metabolism of Lornoxicam can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Lornoxicam.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Lornoxicam.
Valproic AcidThe metabolism of Lornoxicam can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Lornoxicam.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Lornoxicam.
VoriconazoleThe metabolism of Lornoxicam can be decreased when combined with Voriconazole.
WarfarinLornoxicam may increase the anticoagulant activities of Warfarin.
XimelagatranLornoxicam may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Lornoxicam can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Lornoxicam.
Zoledronic acidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lornoxicam.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. doi: 10.1016/j.contraception.2009.12.008. Epub 2010 Jan 27. [PubMed:20399943 ]
  2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. [PubMed:10450786 ]
  3. Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36. [PubMed:17516707 ]
  4. Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5. [PubMed:11846620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. doi: 10.1016/j.contraception.2009.12.008. Epub 2010 Jan 27. [PubMed:20399943 ]
  2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. [PubMed:10450786 ]
  3. Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36. [PubMed:17516707 ]
  4. Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5. [PubMed:11846620 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Rodrigues AD: Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75. Epub 2005 Aug 23. [PubMed:16118328 ]
  2. Martinez C, Blanco G, Garcia-Martin E, Agundez JA: [Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs]. Farm Hosp. 2006 Jul-Aug;30(4):240-8. [PubMed:17022718 ]
  3. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H: Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol. 2005 Jan;59(1):14-7. [PubMed:15606435 ]
  4. Kohl C, Steinkellner M: Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8. [PubMed:10640513 ]
  5. Bonnabry P, Leemann T, Dayer P: Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol. 1996;49(4):305-8. [PubMed:8857077 ]
  6. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  7. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  8. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on August 18, 2010 12:12 / Updated on August 17, 2016 12:24